Polymorphisms in Toll-like receptor genes influence antibody responses to cytomegalovirus glycoprotein B vaccine

BMC Research Notes

Robert H Yolken²  Robert F Pass³  Terri Beaty¹  Roxann G Ingersoll¹  Priya Duggal¹  Genevieve L Wojcik¹  Ravit Arav-Boger² 

[1] Department of Epidemiology Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21231-1000, USA;Department of Pediatrics, Division of Infectious Diseases, Johns Hopkins Hospital, Baltimore, Maryland 21287-4933, USA;Department of Pediatrics, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA

关键词: glycoprotein B vaccine;    single nucleotide polymorphisms;    Toll-like receptors;    Cytomegalovirus;   

Others  :  1166594
DOI  :  10.1186/1756-0500-5-140

 received in 2011-12-12, accepted in 2012-03-13,  发布年份 2012

【 摘 要 】

Background

Congenital Cytomegalovirus (CMV) infection is an important medical problem that has yet no current solution. A clinical trial of CMV glycoprotein B (gB) vaccine in young women showed promising efficacy. Improved understanding of the basis for prevention of CMV infection is essential for developing improved vaccines.

Results

We genotyped 142 women previously vaccinated with three doses of CMV gB for single nucleotide polymorphisms (SNPs) in TLR 1-4, 6, 7, 9, and 10, and their associated intracellular signaling genes. SNPs in the platelet-derived growth factor receptor (PDGFRA) and integrins were also selected based on their role in binding gB. Specific SNPs in TLR7 and IKBKE (inhibitor of nuclear factor kappa-B kinase subunit epsilon) were associated with antibody responses to gB vaccine. Homozygous carriers of the minor allele at four SNPs in TLR7 showed higher vaccination-induced antibody responses to gB compared to heterozygotes or homozygotes for the common allele. SNP rs1953090 in IKBKE was associated with changes in antibody level from second to third dose of vaccine; homozygotes for the minor allele exhibited lower antibody responses while homozygotes for the major allele showed increased responses over time.

Conclusions

These data contribute to our understanding of the immunogenetic mechanisms underlying variations in the immune response to CMV vaccine.

【 授权许可】

   
2012 Arav-Boger et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kenneson A, Cannon MJ: Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007, 17:253-276.
• [2]Yow MD, Demmler GJ: Congenital cytomegalovirus disease-20 years is long enough. N Engl J Med 1992, 326:702-703.
• [3]Griffiths PD, Clark DA, Emery VC: Betaherpesviruses in transplant recipients. J Antimicrob Chemother 2000, 45(Suppl T3):29-34.
• [4]Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G: Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009, 360:1191-1199.
• [5]Fowler KB, Stagno S, Pass RF: Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003, 289:1008-1011.
• [6]Schleiss MR, Bourne N, Bernstein DI: Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J Infect Dis 2003, 188:1868-1874.
• [7]Schleiss MR, Lacayo JC, Belkaid Y, McGregor A, Stroup G, Rayner J, Alterson K, Chulay JD, Smith JF: Preconceptual administration of an alphavirus replicon UL83 (pp 65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 2007, 195:789-798.
• [8]Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK: Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256-1263.
• [9]Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW: Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000, 1:398-401.
• [10]Bieback K, Lien E, Klagge IM, Avota E, Schneider-Schaulies J, Duprex WP, Wagner H, Kirschning CJ, Ter MV, Schneider-Schaulies S: Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol 2002, 76:8729-8736.
• [11]Poland GA: Variability in immune response to pathogens: using measles vaccine to probe immunogenetic determinants of response. Am J Hum Genet 1998, 62:215-220.
• [12]Poland GA, Jacobson RM: The genetic basis for variation in antibody response to vaccines. Curr Opin Pediatr 1998, 10:208-215.
• [13]Hohler T, Reuss E, Evers N, Dietrich E, Rittner C, Freitag CM, Vollmar J, Schneider PM, Fimmers R: Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins. Lancet 2002, 360:991-995.
• [14]Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow RA: HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology 2004, 39:978-988.
• [15]Desombere I, Hauser P, Rossau R, Paradijs J, Leroux-Roels G: Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J Immunol 1995, 154:520-529.
• [16]Pankratz VS, Vierkant RA, O'Byrne MM, Ovsyannikova IG, Poland GA: Associations between SNPs in candidate immune-relevant genes and rubella antibody levels: a multigenic assessment. BMC Immunol 2010, 11:48. BioMed Central Full Text
• [17]Green NM, Marshak-Rothstein A: Toll-like receptor driven B cell activation in the induction of systemic autoimmunity. Semin Immunol 2011, 23:106-112.
• [18]Boehme KW, Guerrero M, Compton T: Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells. J Immunol 2006, 177:7094-7102.
• [19]Yurochko AD, Hwang ES, Rasmussen L, Keay S, Pereira L, Huang ES: The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection. J Virol 1997, 71:5051-5059.
• [20]Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR: Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 2007, 44:1315-1320.
• [21]Hackett DJ, Zhang C, Stefanescu C, Pass RF: Enzyme-linked immunosorbent assay for measurement of cytomegalovirus glycoprotein B antibody in serum. Clin Vaccine Immunol 2010, 17:836-839.
• [22]Soroceanu L, Akhavan A, Cobbs CS: Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 2008, 455:391-395.
• [23]Wang X, Huang DY, Huong SM, Huang ES: Integrin alphavbeta3 is a coreceptor for human cytomegalovirus. Nat Med 2005, 11:515-521.
• [24]Howie BN, Carlson CS, Rieder MJ, Nickerson DA: Efficient selection of tagging single-nucleotide polymorphisms in multiple populations. Hum Genet 2006, 120:58-68.
• [25]Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D: Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006, 38:904-909.
• [26]Finberg RW, Knipe DM, Kurt-Jones EA: Herpes simplex virus and toll-like receptors. Viral Immunol 2005, 18:457-465.
• [27]Kurt-Jones EA, Belko J, Yu C, Newburger PE, Wang J, Chan M, Knipe DM, Finberg RW: The role of toll-like receptors in herpes simplex infection in neonates. J Infect Dis 2005, 191:746-748.
• [28]Ashkar AA, Yao XD, Gill N, Sajic D, Patrick AJ, Rosenthal KL: Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis 2004, 190:1841-1849.
• [29]Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, Mudd S, Shamel L, Sovath S, Goode J, Alexopoulou L, Flavell RA, Beutler B: Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 2004, 101:3516-3521.
• [30]Szomolanyi-Tsuda E, Liang X, Welsh RM, Kurt-Jones EA, Finberg RW: Role for TLR2 in NK cell-mediated control of murine cytomegalovirus in vivo. J Virol 2006, 80:4286-4291.
• [31]Compton T, Kurt-Jones EA, Boehme KW, Belko J, Latz E, Golenbock DT, Finberg RW: Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol 2003, 77:4588-4596.
• [32]Simmen KA, Singh J, Luukkonen BG, Lopper M, Bittner A, Miller NE, Jackson MR, Compton T, Fruh K: Global modulation of cellular transcription by human cytomegalovirus is initiated by viral glycoprotein B. Proc Natl Acad Sci USA 2001, 98:7140-7145.
• [33]Boyle KA, Pietropaolo RL, Compton T: Engagement of the cellular receptor for glycoprotein B of human cytomegalovirus activates the interferon-responsive pathway. Mol Cell Biol 1999, 19:3607-3613.
• [34]Askar E, Ramadori G, Mihm S: Toll-like receptor 7 rs179008/Gln11Leu gene variants in chronic hepatitis C virus infection. J Med Virol 2010, 82:1859-1868.
• [35]Edwards AO, Chen D, Fridley BL, James KM, Wu Y, Abecasis G, Swaroop A, Othman M, Branham K, Iyengar SK, Sivakumaran TA, Klein R, Klein BE, Tosakulwong N: Toll-like receptor polymorphisms and age-related macular degeneration. Invest Ophthalmol Vis Sci 2008, 49:1652-1659.
• [36]Boehme KW, Singh J, Perry ST, Compton T: Human cytomegalovirus elicits a coordinated cellular antiviral response via envelope glycoprotein B. J Virol 2004, 78:1202-1211.
• [37]DeFilippis VR, Alvarado D, Sali T, Rothenburg S, Fruh K: Human cytomegalovirus induces the interferon response via the DNA sensor ZBP1. J Virol 2010, 84:585-598.
• [38]Martin HJ, Lee JM, Walls D, Hayward SD: Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus. J Virol 2007, 81:9748-9758.
• [39]Varani S, Cederarv M, Feld S, Tammik C, Frascaroli G, Landini MP, Soderberg-Naucler C: Human cytomegalovirus differentially controls B cell and T cell responses through effects on plasmacytoid dendritic cells. J Immunol 2007, 179:7767-7776.
• [40]Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G: Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168:4531-4537.
• [41]Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ: The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 2000, 203:55-65.
• [42]Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S, Hartmann G: Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 2005, 174:4043-4050.
• [43]Seubert A, Calabro S, Santini L, Galli B, Genovese A, Valentini S, Aprea S, Colaprico A, D'Oro U, Giuliani MM, Pallaoro M, Pizza M, O'Hagan DT, Wack A, Rappuoli R, De GE: Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci USA 2011, 108:11169-11174.
• [44]Gavin AL, Hoebe K, Duong B, Ota T, Martin C, Beutler B, Nemazee D: Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006, 314:1936-1938.
• [45]Gravel SP, Servant MJ: Roles of an IkappaB kinase-related pathway in human cytomegalovirus-infected vascular smooth muscle cells: a molecular link in pathogen-induced proatherosclerotic conditions. J Biol Chem 2005, 280:7477-7486.
• [46]Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T: IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003, 4:491-496.
• [47]Boehme KW, Singh J, Perry ST, Compton T: Human cytomegalovirus elicits a coordinated cellular antiviral response via envelope glycoprotein B. J Virol 2004, 78:1202-1211.
• [48]DeFilippis VR, Alvarado D, Sali T, Rothenburg S, Fruh K: Human cytomegalovirus induces the interferon response via the DNA sensor ZBP1. J Virol 2010, 84:585-598.